WO1998040097A3 - Coronavirus respiratoire bovin utilise comme vaccin - Google Patents

Coronavirus respiratoire bovin utilise comme vaccin Download PDF

Info

Publication number
WO1998040097A3
WO1998040097A3 PCT/US1998/004392 US9804392W WO9840097A3 WO 1998040097 A3 WO1998040097 A3 WO 1998040097A3 US 9804392 W US9804392 W US 9804392W WO 9840097 A3 WO9840097 A3 WO 9840097A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
bovine respiratory
bovine
coronavirus
enteric coronavirus
Prior art date
Application number
PCT/US1998/004392
Other languages
English (en)
Other versions
WO1998040097A2 (fr
WO1998040097A9 (fr
Inventor
Lisa C Stine
Michael J Mcginley
Gary A Anderson
Douglas L Stine
Karen K Brown
Andre D Dory
Adrian Liem
Original Assignee
Bayer Ag
Immtech Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Immtech Int Inc filed Critical Bayer Ag
Priority to AU63465/98A priority Critical patent/AU725439B2/en
Priority to BR9808226A priority patent/BR9808226A/pt
Priority to NZ337702A priority patent/NZ337702A/en
Priority to KR10-1999-7007847A priority patent/KR100531491B1/ko
Priority to EP98907727A priority patent/EP0975360B1/fr
Priority to JP53963698A priority patent/JP2001519781A/ja
Priority to DE1998635424 priority patent/DE69835424T2/de
Publication of WO1998040097A2 publication Critical patent/WO1998040097A2/fr
Publication of WO1998040097A3 publication Critical patent/WO1998040097A3/fr
Publication of WO1998040097A9 publication Critical patent/WO1998040097A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte à un coronavirus respiratoire bovin et à des coronavirus entériques bovins, se présentant sous forme modifiée, vivante ou inactivée, et à leurs antigènes, qui sont utilisés comme vaccin de protection contre les maladies à coronavirus entérique bovin ou à coronavirus respiratoire bovin, ainsi qu'à des procédés de fabrication et d'utilisation de ces vaccins.
PCT/US1998/004392 1997-03-10 1998-03-04 Coronavirus respiratoire bovin utilise comme vaccin WO1998040097A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU63465/98A AU725439B2 (en) 1997-03-10 1998-03-04 Bovine respiratory coronavirus as a vaccine
BR9808226A BR9808226A (pt) 1997-03-10 1998-03-04 Coronavìrus respiratório bovino como uma vacina
NZ337702A NZ337702A (en) 1997-03-10 1998-03-04 Bovine respiratory coronavirus (BRCV) or bovine enteric coronavirus (BECV) as a vaccine for protecting against diseases caused by both BECV and BRCV
KR10-1999-7007847A KR100531491B1 (ko) 1997-03-10 1998-03-04 백신으로서 소 호흡 코로나바이러스
EP98907727A EP0975360B1 (fr) 1997-03-10 1998-03-04 Coronavirus respiratoire bovin utilise comme vaccin
JP53963698A JP2001519781A (ja) 1997-03-10 1998-03-04 ワクチンとしてのウシの呼吸器および腸コロナウイルス
DE1998635424 DE69835424T2 (de) 1997-03-10 1998-03-04 Boviner atmungs- und darmcoronavirus als impfstoff

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81431197A 1997-03-10 1997-03-10
US08/814,311 1997-03-10

Publications (3)

Publication Number Publication Date
WO1998040097A2 WO1998040097A2 (fr) 1998-09-17
WO1998040097A3 true WO1998040097A3 (fr) 1999-01-14
WO1998040097A9 WO1998040097A9 (fr) 1999-02-25

Family

ID=25214684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004392 WO1998040097A2 (fr) 1997-03-10 1998-03-04 Coronavirus respiratoire bovin utilise comme vaccin

Country Status (13)

Country Link
EP (1) EP0975360B1 (fr)
JP (1) JP2001519781A (fr)
KR (1) KR100531491B1 (fr)
CN (1) CN1283315C (fr)
AT (1) ATE334697T1 (fr)
AU (1) AU725439B2 (fr)
BR (1) BR9808226A (fr)
CA (1) CA2231591A1 (fr)
DE (1) DE69835424T2 (fr)
DK (1) DK0975360T3 (fr)
ES (1) ES2270508T3 (fr)
NZ (1) NZ337702A (fr)
WO (1) WO1998040097A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
CA2471968C (fr) * 2001-10-06 2013-07-23 Merial Limited Cides nucleiques immunostimulants et utilisations associees
US7375202B2 (en) * 2003-03-24 2008-05-20 The University Of Hong Kong Human virus causing severe acute respiratory syndrome (SARS) and uses thereof
EP1649053A4 (fr) * 2003-06-18 2006-10-18 Chinese Nat Human Genome Ct Sh Caracterisation des stades les plus precoces du virus du syndrome respiratoire aigu severe (sras), et applications
CN1318580C (zh) * 2003-07-10 2007-05-30 北京科兴生物制品有限公司 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法
US8440203B2 (en) 2009-11-06 2013-05-14 Intervet Inc. Methods of immunizing pregnant heifers at three months of gestation
EP3188750B1 (fr) * 2014-09-03 2020-03-11 Intervet International B.V. Coronavirus bovin atténué et vaccins associés
CN111117975A (zh) * 2020-01-03 2020-05-08 西南民族大学 牛冠状病毒he基因重组株及其制备的灭活疫苗和应用
CN113322241B (zh) * 2021-05-14 2023-06-13 金宇保灵生物药品有限公司 一种牛副流感病毒3型病毒株bpiv3-nm及其应用
CN117286111B (zh) * 2023-03-13 2024-06-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 牛冠状病毒分离株、稳定表达牛冠状病毒n蛋白细胞系及在构建反向遗传操作系统中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034686A1 (fr) * 1994-06-15 1995-12-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Isolation et diagnostic de coronavirus
WO1996041874A1 (fr) * 1995-06-12 1996-12-27 Kansas State University Research Foundation Nouveau vaccin multivalent a base de virus corona bovin et methode de traitement de l'infection au virus corona bovin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034686A1 (fr) * 1994-06-15 1995-12-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Isolation et diagnostic de coronavirus
WO1996041874A1 (fr) * 1995-06-12 1996-12-27 Kansas State University Research Foundation Nouveau vaccin multivalent a base de virus corona bovin et methode de traitement de l'infection au virus corona bovin

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C. MEBUS ET AL.: "Neonatal calf diarrhea: propagation, attenuation, and characteristics of a coronavirus-like agent.", AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 34, no. 2, 1973, Schaumburg, USA, pages 145 - 150, XP002084560 *
E. THURBER ET AL.: "Field trial evaluation of a reo-coronavirus calf diarrhea vaccine.", CANADIAN JOURNAL OF COMPARATIVE MEDICINE, vol. 41, no. 2, April 1977 (1977-04-01), Ottawa, Canada, pages 131 - 136, XP002084558 *
J. STORZ ET AL.: "Coronavirus isolation from nasal swap samples in cattle with signs of respiratory-tract disease after shipping.", JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, vol. 208, no. 9, 1 May 1996 (1996-05-01), Chicago, IL, USA, pages 1452 - 1455, XP002084556 *
K. MÖSTL ET AL.: "Incidence of diarrhoea and of rotavirus- and coronavirus-shedding in calves, whose dams had been vaccinated with an experimental oil-adjuvanted vaccine containing bovine rotavirus and bovine coronavirus.", JOURNAL OF VETERINARY MEDICINE, vol. 35, no. 3, April 1988 (1988-04-01), Hamburg, Germany, pages 186 - 196, XP002084557 *
L. MYERS ET AL.: "Colostral and milk antibody titers in cows vaccinated with a modified live-rotavirus-coronavirus vaccine.", JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, vol. 181, no. 5, 1 September 1982 (1982-09-01), Chicago, IL, USA, pages 486 - 488, XP002084559 *

Also Published As

Publication number Publication date
EP0975360B1 (fr) 2006-08-02
KR100531491B1 (ko) 2005-11-28
DE69835424D1 (de) 2006-09-14
EP0975360A2 (fr) 2000-02-02
AU6346598A (en) 1998-09-29
NZ337702A (en) 2001-05-25
CN1283315C (zh) 2006-11-08
ATE334697T1 (de) 2006-08-15
DK0975360T3 (da) 2006-11-27
CN1250380A (zh) 2000-04-12
AU725439B2 (en) 2000-10-12
CA2231591A1 (fr) 1998-09-10
JP2001519781A (ja) 2001-10-23
ES2270508T3 (es) 2007-04-01
KR20000075775A (ko) 2000-12-26
BR9808226A (pt) 2000-05-16
WO1998040097A2 (fr) 1998-09-17
DE69835424T2 (de) 2007-02-08

Similar Documents

Publication Publication Date Title
GB2322801B (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
ES2140076T3 (es) Vacunas que contienen una saponina y un esterol.
MX9604907A (es) Vacuna de combinacion de virus para la enfermedad de newcastle.
TR200002855T2 (tr) Raloksifenin solunum yolu ile veya burundan uygulanması.
FI964681A (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
GR1002893B (el) Φαρμακευτικες συνθεσεις με εντερικη επικαλυψη
BG104511A (en) Spheroids, preparation method and pharmaceutical compositions
DE60210456D1 (de) Solubisierung von kapseln polysacchariden
SE9704546D0 (sv) Novel compounds
WO1998040097A3 (fr) Coronavirus respiratoire bovin utilise comme vaccin
AU2001258373A1 (en) Method for identifying helicobacter antigens
HUP9801572A2 (hu) Chlamydia-vakcinák
AP9901666A0 (en) Leishmania vaccine.
WO1999057278A3 (fr) Immunisation et traitement anti-infectieux
ES2184987T3 (es) Formas de administracion solidas de liberacion instantanea y procedimiento para su preparacion.
IL141443A0 (en) Vaccine comprising cytokine-induced heat shock proteins (hsp)
WO1999020305A8 (fr) Vaccins veterinaires
AP9801399A0 (en) Zona pellucida proteins for contraception.
PT796256E (pt) Novos processos de preparacao da ranitidina
MD1473G2 (ro) Remediu antiherpetic
AU7728296A (en) Hemoregulatory compounds
ECSP961731A (es) Vacunas
UA23872A (uk) Лікувальний препарат (його варіанти)
UA49450A (uk) Вакцина інактивована рекомбінантна проти інфекційного ринотрахеїту великої рогатої худоби
UA18990A (uk) Зубhий імплаhтат

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98803245.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 4, 6, 8, 11 AND 12, DESCRIPTION, REPLACED BY NEW PAGES 4, 6, 8, 11 AND 12; PAGES 31 AND 32, CLAIMS, REPLACED BY NEW PAGES 31 AND 32; AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

WWE Wipo information: entry into national phase

Ref document number: 1998907727

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997007847

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 539636

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 63465/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 337702

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998907727

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997007847

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 63465/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1019997007847

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998907727

Country of ref document: EP